Pablo Tebas

faculty photo
Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
Investigator of the Vaccine Trials Network, University of Pennsylvania
Director, Developmental Core Center for AIDS research (CFAR), Perelman School of Medicine, University of Pennsylvania
Department: Medicine

Contact information
Academic Address: 502 Johnson Pavilion. Infectious Disease office.
Clinical Office: Perelman Center for Advanced Medicine Infectious Diseases. 3600 Civic Center Boulevard.
Philadelphia, Pa 19104
Office: 215-349-8091
Fax: 215-349-8011
Universidad Autónoma de Madrid, Spain, 1985.
Permanent link

Description of Research Expertise

My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.
I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.

Description of Itmat Expertise

Dr. Tebas is involved in clinical trials evaluating new therapies for HIV infection including gene therapy and therapeutic DNA vaccines. His research interests include antiretroviral therapy, treatment of virologic failures, simplification strategies as well studying the metabolic complications associated with antiretroviral treatment.

Selected Publications

Lo Re, V., 3rd, Lynn, K., Stumm, E. R., Long, J., Nezamzadeh, M. S., Baker, J. F., Hoofnagle, A. N., Kapalko, A. J., Mounzer, K., Zemel, B. S., Tebas, P., Kostman, J. R., Leonard, M. B.: Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women. J Infect Dis March 2015.

Sawinski, D., Forde, K. A., Eddinger, K., Troxel, A. B., Blumberg, E., Tebas, P., Abt, P. L., Bloom, R. D.: Superior outcomes in HIV-positive kidney transplant patients compared with HCV-infected or HIV/HCV-coinfected recipients. Kidney Int March 2015.

Morrow, M. P., Tebas, P., Yan, J., Ramirez, L., Slager, A., Kraynyak, K., Diehl, M., Shah, D., Khan, A., Lee, J., Boyer, J., Kim, J. J., Sardesai, N. Y., Weiner, D. B., Bagarazzi, M. L.: Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals. Mol Ther 23(3): 591-601, March 2015.

Ramirez, L. A., Arango, T. A., Thompson, E., Naji, M., Tebas, P., Boyer, J. D.: High IP-10 levels decrease T cell function in HIV-1-infected individuals on ART. J Leukoc Biol 96(6): 1055-63, December 2014.

Jacobson, J. M., Wang, H., Bordi, R., Zheng, L., Gross, B. H., Landay, A. L., Spritzler, J., Routy, J. P., Benson, C., Aberg, J., Tebas, P., Haas, D. W., Tiu, J., Coughlin, K., Purdue, L., Sekaly, R. P., Aids Clinical Trials Group A Protocol Team: A Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery in Patients with HIV-1 Infection on Antiretroviral Therapy. J Acquir Immune Defic Syndr 66(4): 399-406, August 2014.

Tebas, P., Sension, M., Arribas, J., Duiculescu, D., Florence, E., Hung, C. C., Wilkin, T., Vanveggel, S., Stevens, M., Deckx, H., Echo,, Thrive Study Groups: Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Clin Infect Dis 59(3): 425-34, August 2014.

Ramirez, L. A., Daniel, A., Frank, I., Tebas, P., Boyer, J. D.: Seroprotection of HIV-infected subjects after influenza A(H1N1) vaccination is directly associated with baseline frequency of naive T cells. J Infect Dis 210(4): 646-50, August 2014.

Jacobson, J. M., Wang, H., Bordi, R., Zheng, L., Gross, B. H., Landay, A. L., Spritzler, J., Routy, J. P., Benson, C., Aberg, J., Tebas, P., Haas, D. W., Tiu, J., Coughlin, K., Purdue, L., Sekaly, R. P., Aids Clinical Trials Group A Protocol Team: A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr 66(4): 399-406, August 2014.

Sims, K. D., Lemm, J., Eley, T., Liu, M., Berglind, A., Sherman, D., Lawitz, E., Vutikullird, A. B., Tebas, P., Gao, M., Pasquinelli, C., Grasela, D. M.: Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection. Antimicrob Agents Chemother 58(6): 3496-3503, June 2014.

Arribas, J. R., Pialoux, G., Gathe, J., Di Perri, G., Reynes, J., Tebas, P., Nguyen, T., Ebrahimi, R., White, K., Piontkowsky, D.: Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 14(7): 581-9, June 2014.

back to top
Last updated: 10/06/2015
The Trustees of the University of Pennsylvania